Forskolin

目录号:S2449 别名: Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。

规格 价格 库存 购买数量  
RMB 1144.16 现货
RMB 903.37 现货
RMB 2229.31 现货
RMB 3029.97 现货
RMB 4679.71 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献18篇:

客户使用该产品的3个实验数据:

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Western blot analysis shows pERK levels after 8 hours treatment with forskolin. AC activation with 10 μmol/L forskolin (F).

    Mol Cancer Res, 2017, 15(12):1792-1802. Forskolin purchased from Selleck.

  • Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

产品安全说明书

cAMP抑制剂选择性比较

生物活性

产品描述 Forskolin在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。
靶点
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外研究

Forskolin可以使膜,细胞或组织制备液中cAMP含量上升。Forskolin 不仅可以活化AC 而且可以与某些其它蛋白相互作用,包括葡萄糖转运蛋白和离子通道。Forskolin能够促进9种不同独立AC形式的活化,虽然对AC9效率有点低,这可以用于提供一种鉴定和量化G蛋白 (Gs)–AC复合物高亲和性结合位点的方法。G蛋白偶联受体活化G蛋白有助于细胞中Forskolin刺激的cAMP 产生,因为 G蛋白-Forskolin对AC活性有增强作用[1]。Forskolin在不与细胞表面受体相互作用前提下刺激腺苷酸环化酶活性。在脂肪细胞中Forskolin's促进 cAMP产生进而可以抑制嗜碱性粒细胞和肥大细胞脱颗粒作用以及组胺释放,降低血压、眼内压,抑制血小板聚集,促进血管舒张,支气管扩张和甲状腺激素分泌,刺激脂肪分解。Forskolin 抑制血小板活化因子 (PAF)的结合, 这种抑制不依赖于cAMP形成可能是 Forskolin's 直接作用于 PAF或者通过干扰PAF与它的受体结合实现的。Forskolin似乎对多种膜转运蛋白也有效果并且可以抑制脂肪细胞,红细胞,血小板,和其他细胞中的葡萄糖运输。Forskolin也被用于治疗青光眼[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 M3;Cd2Z2dmO2aX;uJGF{e2G7 M13XXVExKM7:TR?= NU\yfVltPiCq NVjUSFlPcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? M1r0SVI3PDN3NEm4
Mo-DCs NUTRT254TnWwY4Tpc44hSXO|YYm= MVW1NEDPxE1? NVzVcVd{OjUkgJno NGO1eVJxem:vb4Tld{BKVC1{MzDwdo9lfWO2aX;uJIlvKHSqZTDzeZBmem6jdHHueEBw\iC8eX3vd4FvKHO2aX31cIF1\WRiTX:tSGN{yqB? NGHKOVUzPjRzMkm0PC=>
RBMECs  M{LrZmZ2dmO2aX;uJGF{e2G7 NWX3SVVGPcLizszN NF[wUlcyyqCq MUficI9kc3NidHjlJHJi[zFiaX7hZ5RqfmG2aX;uJIlv\HWlZXSgZpkhTU2DUD3JTS=> Mn7sNlY{PThyM{m=
INA-6 MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mlf6NE0yODBizszN NUHHb2V4PzMkgJno MVjpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MWKyOlMxPjZ{NB?=
OPM-2 M1;2[GNmdGxiVnnhZoltcXS7IFHzd4F6 M{PXU|AuOTByIN88US=> NFHiNYs4OuLCiXi= NGTodFFqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmHWNlY{ODZ4MkS=
U266 M4HpbWNmdGxiVnnhZoltcXS7IFHzd4F6 Mn62NE0yODBizszN NGHu[5M4OuLCiXi= NF:5OW5qdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> MXyyOlMxPjZ{NB?=
H929 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWqwMVExOCEQvF2= M1SyfVcz6oDLaB?= NH;WNIdqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXrsOYNnOjZ|ME[2NlQ>
RPMI 8226 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{DBfFAuOTByIN88US=> Mli4O|LjiImq NYTne|RXcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NGHTVXQzPjNyNk[yOC=>
MDCK  NWHXSIdVTnWwY4Tpc44hSXO|YYm= NGHUPVEyOCEEtV2= MVeyOEBp NXnRUopxTE2VTx?= M1XxW5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKFSJRj5OtlEh[W6mIFPUS2bDqA>? M2jjfVI3OjB{M{Wy
MDCK  MYnGeY5kfGmxbjDBd5NigQ>? NFOzdVgyOCEEtV2= NIXV[mQzPCCq M{HV[mROW09? M2[yPIlvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? MlTRNlYzODJ|NUK=
Spinal cords  MmLRSpVv[3Srb36gRZN{[Xl? MkHqNeKh|ryP MkTiN|AhdWmw Ml7Ud5RqdXWuYYTld{BkSU2SIHzleoVtew>? MYSyOlEzPjl{Nh?=
BeWo  Mlz4SpVv[3Srb36gRZN{[Xl? MXqyOgKBkc7:TR?= NEDLUnozPC92OD:3NkBp MXvs[YFleyC2bzDhckBqdmO{ZXHz[UBqdiC2aHWg[ZhxemW|c3nvckBw\iCxdHjldkBnfXOrb36gcYFzc2W{cx?= M4DodlI3ODV|NUS5
bovine oocytes NI\DS5BHfW6ldHnvckBCe3OjeR?= MX:xNFDDqM7:TR?= NEP4elkyOsLiaB?= M4q5SolvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ NGXBRpAzPjB3MU[xNS=>
Caco-2  M1nBVGZ2dmO2aX;uJGF{e2G7 M4rHTlAvOS9zL{GwJO69VQ>? Mo\nNlDDqG2rbh?= NWLhcY9UcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ2FOWCCuZY\lcJM> NGHGdmYzPjB2OUGwNi=>
Caco-2  NVvSe4tqTnWwY4Tpc44hSXO|YYm= NYi3NItTOC5zL{GvNVAh|ryP MV:yOEBp M{G4XYlv[3KnYYPld{BOWlB{IIDyc5RmcW5ibHX2[Yw> MnTPNlYxPDlzMEK=
AML-12  Ml\BSpVv[3Srb36gRZN{[Xl? MmjpNlAh|ryP NFfBbZA{KGh? NUjzXJc3fXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=> MofHNlYxPDh7OEW=
AML-12  NEnRS21HfW6ldHnvckBCe3OjeR?= NV\XRWZOOjBizszN MnXxNU05KGh? M{e5bYlv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> M4XLfVI3ODR6OUi1
AML-12  MXfGeY5kfGmxbjDBd5NigQ>? M2nCUVIxKM7:TR?= NFXEdIQ{KGh? MmrpeZAuemWpdXzheIV{yqCSZ3OxZUzDqFCncHPrMEBidmUEoFe2dIPDqG2UTlGgcIV3\Wy| MUSyOlA1QDl6NR?=
AML-12  MkL3SpVv[3Srb36gRZN{[Xl? M1zSfVIxKM7:TR?= M{nITFMhcA>? NU\QfHI5cW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25ib3[gR3JVSzMEoB?= MVWyOlA1QDl6NR?=
RBMECs NF2wO|lHfW6ldHnvckBCe3OjeR?= NYj3XVhpPcLizszN NEfrbVEyKGh? MmDobY5pcWKrdIOgSW1CWC2LST3pcoR2[2WmIHnuZYN1cX[jdHnvckBw\iCUYYCxxsA> MUmyOlA1PDZ4Mx?=
EndoC-βH1 MljaSpVv[3Srb36gRZN{[Xl? NXjqSppWPcLizszN M3HzS|EhcA>? MYnwc5RmdnSrYYTld{BodHWlb4PlMYlv\HWlZXSgbY5{fWyrbjDz[YNz\XSrb36gbY4hfGinIIDy[ZNmdmOnIH;mJIdtfWOxc3W= MVuyOlAzQDV4Mh?=
EndoC-βH1 M1rXWmZ2dmO2aX;uJGF{e2G7 NVHyPFRqPcLizszN MXuxJIg> NY\1WmlJdGWjZIOgeI8h[SC|dILvcoch[0GPUDDpcoNz\WG|ZR?= NUjlPY1rOjZyMki1OlI>
SH-SY5Y NHHLO3NHfW6ldHnvckBCe3OjeR?= NWXsOVN4OzBizszN MUWzNEBucW5? NXXLVo1zTE2VTx?= NUe2U5dze2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGGldHn2ZZRqd25ib3[gVGtC Ml3kNlYxOjVzM{e=
PC-3 M1T3UWZ2dmO2aX;uJGF{e2G7 MlLhOFAhyrWP M1XH[lIhcA>? M1fyVGROW09? MUXs[YFleyC2bzDQVFJCKGGldHn2ZZRqd25? MWWyOlAzOzh|Nh?=
PC-3 MlqyR4VtdCCYaXHibYxqfHliQYPzZZk> NVLJd4RQPDBiwsXN NWnSfoFpOjRxNEivO|IhcA>? NU\xUFdxTE2VTx?= NYHpfmpF\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= M17PdFI3ODJ|OEO2
SCG MV\GeY5kfGmxbjDBd5NigQ>? MW[yNEDPxE4EoB?= MYrEUXNQ Mn7wdoV3\XK|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>? NYDt[W11OjV7NkKxN|I>
HEK-293 MWTGeY5kfGmxbjDBd5NigQ>? M1LSV|M2KM7:TdMg Mni5SG1UVw>? MVTpcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 MonRNlU6PjJzM{K=
SCG Mn[4SpVv[3Srb36gRZN{[Xl? NE\YV5QyODBizszNxsA> MUDEUXNQ NX35O|lMemWmdXPld{B1cGViZYjjbZRi[mmuaYT5JI9nKFOFRzDu[ZVzd26| MYCyOVk3OjF|Mh?=
PCCL3 NWDBcohtTnWwY4Tpc44hSXO|YYm= M2niSlExKML3TR?= M4XycVI1KGh? NELpNphmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= MU[yOVk3ODl3Nh?=
3T3-L1 preadipocytes MWXGeY5kfGmxbjDBd5NigQ>? NWG5XW1ROTBizszNxsA> NIW0bmMyOiCq MlXFbY5lfWOnczDDVmVDKHCqb4PwbI9zgWyjdHnvckBidmRiQz;FRnDPuiCneIDy[ZN{cW:w NV3MbVJ{OjV7MkiwOVg>
H295R  MVjGeY5kfGmxbjDBd5NigQ>? NIOyeHAyOMLizszN NGO0XlI1QMLiaB?= Ml;IbY5kemWjc3XzJJN1\XKxaXSgcYV1[WKxbHn0[ZMhcW5idHjlJIFv\HKxZ3XuMEBucW6ncnHsc{0h[W6mIHfseYNw[2:{dHnjc4llKHCjdHj3ZZl{ NX[ycId{OjV6Nkm1OVY>
PBMC MUXGeY5kfGmxbjDBd5NigQ>? MkmyOVDDqM7:TR?= MnvKNlTDqGkEoB?= M1jMWYlvcGmkaYTzJJRp\SCrbnPy[YF{\WRic3XjdoV1cW:wIH;mJHRPTiCrbnT1Z4VlKGK7IITo[UBFWEV? MkDlNlU5PjZyN{m=
GLUTag  MYfGeY5kfGmxbjDBd5NigQ>? NHvVS2kyOOLCidM1US=> NEfkRXMxNzJxNDDo M1K2OZN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> NHy0SFkzPTh|Mk[zNS=>
GLUTag  MYnGeY5kfGmxbjDBd5NigQ>? M{P5fFEx6oDLwsXN NYn3Z2xSPCCq MUPpcoNz\WG|ZYOgeIhmKHCFUlXCJIxmfmWuczD3bZRpKHSqZTDJRm1Z MXiyOVg{OjZ|MR?=
BAECs MmTkSpVv[3Srb36gRZN{[Xl? NHLiWoczPSEQvF2= M2\UUFI1KGh? NWfpVWF5\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> MkDVNlU4QTh6Mk[=
PC12 M2OydWZ2dmO2aX;uJGF{e2G7 NF61eo0zPcLizszN MWe0PEBp MXzhZ5RqfmG2ZYOgZ2FOWA>? M3XQOVI2PzZ7M{C1
GH3 M1\w[WZ2dmO2aX;uJGF{e2G7 MWSxxsDPxE1? M4TLXVYucA>? M3nNeYF1fGWwdXH0[ZMhfGinIHPvdpJmdGG2aX;uJIJmfHenZX6gVHJNKGGwZDDCcYFtOSCneIDy[ZN{cW:w NF;xXZIzPTd{N{CxPC=>
GH3 NYHJVVlvTnWwY4Tpc44hSXO|YYm= NITGNXAyyqEQvF2= NHjoeYI3NWh? MojKbY5lfWOnczDQVmwh[W6mIFLtZYwyNCCkdYSgco91KEOub3PrMEBuWk6DIHX4dJJme3Orb36= NXn6W4xFOjV5MkewNVg>
BeWo NW\BeWN6TnWwY4Tpc44hSXO|YYm= NYXtVmRROTEkgJtOwG3DqA>? NVfL[W9yPzJiaB?= M4jSR2ROW09? M{K3bI1m\GmjdHXzJGJmX29iY3XscEBlcW[oZYLlcpRq[XSrb36= MXeyOVcyOzR{NR?=
oocytes NYr3WJA2TnWwY4Tpc44hSXO|YYm= NX:wflhIPSEQvF2= MYqyOEBp NYHUR4dw[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= MkfONlU4ODd6NUS=
SC M2TPVWZ2dmO2aX;uJGF{e2G7 NX;CNXVrOC53IN88US=> NYTid5ZjOjRiaB?= NXfpdVkxdWmvaXPrd{B1cGViZX\m[YN1KG:oIHPBUXAh[W6jbH;nd{BwdiCRMTDhcoQhVUKSIHX4dJJme3Orb36= M4fzcFI2PzB3OEe0
SC MX7GeY5kfGmxbjDBd5NigQ>? NGmxeHkxNjVizszN NI\6VHc4OiCq NFLXUVRqdmO{ZXHz[ZMh[m:2aDDLdo95NTJyIHHu[EBQOSCneIDy[ZN{cW:wIHnuJIF5d25vcnXsZZRm\CCVQ4OgZpV1KG:wbImgT5JwgC1{MNMg M1XRNVI2PzB3OEe0
UACC-647  MonMSpVv[3Srb36gRZN{[Xl? MYPEUXNQ NGDlVIFt\WGmczD0c{BiKHKrc3WgbY4h[0GPUDDs[ZZmdHNiKFXDOVDDqD4EoEKwMlM6yqEQvF2p M1KzXFI2PzB|MEK1
UACC-647  M{CwO2Z2dmO2aX;uJGF{e2G7 NFP1eJgyOMLizszN MoHpNVUhdWmw MXPEUXNQ Mn7ZbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> Mn3ONlU4ODNyMkW=
UACC-647  M3iwbmZ2dmO2aX;uJGF{e2G7 M4TOXFExyqEQvF2= NHPCUXcyPSCvaX6= NF24cXBFVVOR NYT0WlBPcW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li Mnf2NlU4ODNyMkW=
SH-SY5Y  M2jQdmZ2dmO2aX;uJGF{e2G7 NYSyVmNLOTEEoN88US=> NX\SdmZMOcLiaNMg M1T1SYlv[3KnYYPld{BNXUNiYXP0bZZqfHl? NYfXNGtVOjV3OUe0N|M>
SH-SY5Y  MWLGeY5kfGmxbjDBd5NigQ>? MorBNVDDqM7:TR?= MUGxxsBpyqB? MmSxbY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= NXrXcYNrOjV3OUe0N|M>
hADSCs NX;ld45uTnWwY4Tpc44hSXO|YYm= NYXHfGxpPeLCidM1US=> MXmzNEBucW5? MmjSbY5kemWjc3XzJINCVVBibHX2[Yx{ NG\YSVgzPTV7MUmwPC=>
HEK293  NGC2S21HfW6ldHnvckBCe3OjeR?= MkT3OgKBkcL3TR?= NIPqUYw{OCCvaX6= MnvBbY5kemWjc3XzJINCVVBibHX2[Yx{ MUWyOVU6OTlyOB?=
3T3-L1 NWfTO4xETnWwY4Tpc44hSXO|YYm= M4DOcFIvPS93IN88US=> MWiyOEBpyqB? MUHzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCDVFfMJJBzd3SnaX6g[ZhxemW|c3nvckBifCCjbHyg[I9{\XNidHXzeIVl NV;WUoxWOjV3OUC1PVc>
OCI-Ly1  NVX2cllZTnWwY4Tpc44hSXO|YYm= MXm0NOKh|ryP M4fqU|HDqGkEoB?= M2jVcmROW09? M1LwSolv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z MUmyOVU4PjJ{MB?=
OCI-Ly18  M2WwcmZ2dmO2aX;uJGF{e2G7 M3;yTVQxyqEQvF2= NET4O40yyqCqwrC= NWTmTFRiTE2VTx?= MWfpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= MnLMNlU2PzZ{MkC=
BeWo NYDvPXFzTnWwY4Tpc44hSXO|YYm= Mo\XNlDDqML3TR?= MlL5OFjDqGh? NWDqd3dDTE2VTx?= MVHpcoNz\WG|ZYOgeIhmKGSrZn\ldoVvfGmjdHnvckBw\iCEZWfvJINmdGy| NH:2XmQzPTV4Nke0NC=>
BeWo M2Pw[2Z2dmO2aX;uJGF{e2G7 M3jyeFIxyqEEtV2= NF7GfWk1QMLiaB?= Mor4SG1UVw>? MUTpcoNz\WG|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>? NIe1W4QzPTV4Nke0NC=>
LNCaP  MnLCSpVv[3Srb36gRZN{[Xl? M2fweVExyqEQvF2= MoHaNVIhcMLi NEnS[2VFVVOR NGrPbnZqdmS3Y3XzJIEh\HKjbXH0bYMhcW6lcnXhd4Uhd2ZiQ2LFRlEh[WO2aY\peJk> M1PMVlI2PTR6MEm5
ThGCs  MV3GeY5kfGmxbjDBd5NigQ>? NVPKb2U4OTEkgJtOwG0> MlLNOQKBkmh? NW\FRlY2[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy MWWyOVQ{OzB{Nx?=
ThGCs  M4O2TWZ2dmO2aX;uJGF{e2G7 M1nuWlEx6oDMzszN NUL3fFlCPOLCini= MkPhbY5kemWjc3XzJGNwS2x{LXnu[JVk\WRiRVTONuKh\2WwZTDlfJBz\XO|aX;u MYmyOVQ{OzB{Nx?=
ThGCs  MWfGeY5kfGmxbjDBd5NigQ>? NEThO2MyOOLCit88US=> MVWzJIg> Ml\nbY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCKMl:yJI9vKEWGTkKgcXJPSQ>? MoG0NlU1OzNyMke=
RBMECs Mn3wSpVv[3Srb36gRZN{[Xl? NH;Pb4QxNjB3L{CuOU82KM7:TR?= NInN[YkxNjJ3IHi= M2S5N4lv[3KnYYPld{BkSU2SIHPvcoNmdnS{YYTpc44> MnLDNlU1OTZ4NUG=
RBMECs MlzBSpVv[3Srb36gRZN{[Xl? NH3udlM2yqEQvF2= MVWxJIg> NFL0b4pjdG:la4OgeIhmKGGldHn2ZZRqd25ib3[gVohwSS:UT1PLJIlv\HWlZXSgZpkhTU2DUD3JTS=> NInBd2IzPTRzNk[1NS=>
RBMECs MYTGeY5kfGmxbjDBd5NigQ>? NF\6TVE2yqEQvF2= M2\TTFEhcA>? NXnqeJhSeHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn MlPQNlU1OTZ4NUG=
RBMECs MXvGeY5kfGmxbjDBd5NigQ>? M4DPPVXDqM7:TR?= MnGzNUBp MVfwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? MlS4NlU1OTZ4NUG=
RBMECs M{[xSWZ2dmO2aX;uJGF{e2G7 MUG1xsDPxE1? NEjQeYkyKGh? MlnobY5pcWKrdIOgeIhmKGSnY4LlZZNm\CCxZjDhcY92dnRib3[gXm8uOSCrbjDNSpMhcW6mdXPl[EBjgSCHTVHQMWlK NVnyN4U5OjV2MU[2OVE>
RBMECs NXPKfFlnTnWwY4Tpc44hSXO|YYm= M3Tq[lXDqM7:TR?= Mn63NUBp M2f5eZJmfmW{c3XzJJRp\SClaHHu[4V{KGmwIGrPMVEh\Gm|dILpZpV1cW:wIIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdB?= NXPJ[G5tOjV2MU[2OVE>
RBMECs M{HDVmZ2dmO2aX;uJGF{e2G7 MX21xsDPxE1? NUXneHFWOSCq NEfGcmdjdG:la4OgeIhmKEWPQWCtTWkucW6mdXPl[EBkcGGwZ3WgbY4hVUyFIIDoc5NxcG:{eXzheIlwdg>? MlvZNlU1OTZ4NUG=
RBMECs NGX6TGFHfW6ldHnvckBCe3OjeR?= NXvJWpdEPcLizszN M1HMbFEhcA>? MnW5Zoxw[2u|IITo[UBi[3SrbjDjfZRwe2unbHX0c44hemWjcoLhcodmdWWwdDDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboVCpC=> MkfyNlU1OTZ4NUG=
Primary bovine chondrocytes NUH5OZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TlS|XPxE1? MlzUOFghcA>? M3:1W5JmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz NHPCWlIzPTRyNkCxOi=>
EM1  NIfRUZhHfW6ldHnvckBCe3OjeR?= NIS0VW0yPeLCit88US=> MXG0PEBp MYjy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:owrDMTWbDqG:{wrDQWGdUOsLiaX9CpGNCVFJvIH;yxsBGWEGFMj3zbYxmdmOnZDDFUVEh[2WubIRCpC=> NWXmVXd5OjV|N{i2OlE>
BeWo  NXr2Z4NSTnWwY4Tpc44hSXO|YYm= NVnTPJNDOjEEoNM1US=> NHu1XoI1QMLiaNMg M1fZc2ROW00EoB?= M3i3PIlv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? MU[yOVM3OjJ4MB?=
BeWo  NHiyV21HfW6ldHnvckBCe3OjeR?= NEnXO3gzOMLiwsXN NY\TUlNEPDkEoHlCpC=> NEjsZ3dFVVORwrC= NW\kdnJl\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhXE2HTV[xOi=> NH;4W|gzPTN4MkK2NC=>
BeWo  MYLGeY5kfGmxbjDBd5NigQ>? NGSyXHEzOMLiwsXN NEXsVZE1QMLiaNMg MXrEUXNQyqB? MkS5[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF? M33P[lI2OzZ{Mk[w
granulosa cells MnXISpVv[3Srb36gRZN{[Xl? NWHwcYFLOTBizszN M4P5NlEzNzJ2IHi= MoDrbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= MoDwNlU{OzlzMEW=
granulosa cells Mlq2SpVv[3Srb36gRZN{[Xl? NYLWc2xIOTBizszN MV[xNk8zPCCq M2XjWYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIILldI9zfGW{IHHjeIl3cXS7IH\vdkB1cGVibH;u[4V{fCCocnHncYVvfCBq4pkSPFU1NytzOGLHV|IvVFWFKR?= MYCyOVM{QTFyNR?=
granulosa cells MUHGeY5kfGmxbjDBd5NigQ>? NI\0bXcyOCEQvF2= MUeyOEBp NFTEVndqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 NEXVSGozPTN|OUGwOS=>
granulosa cells MVjGeY5kfGmxbjDBd5NigQ>? M3X0Z|ExKM7:TR?= NHLCdJczPCCq M4L0cIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> M4fuN|I2OzN7MUC1
SK-N-AS  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVSxNEDPxE4EoB?= NYTkZ49xOjRxNEigbC=> NHu1XVVmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh NUfONVBnOjV{Nk[wOlM>
SK-N-AS  Mlr5SpVv[3Srb36gRZN{[Xl? M2\rbVExKM7:TdMg NX3XOXBKOjRiaB?= M3S5Oolv[3KnYYPld{B1cGViY1HNVEBt\X[nbIRCpC=> Ml3KNlUzPjZyNkO=
SK-N-AS  M3vsTGZ2dmO2aX;uJGF{e2G7 MVmxNEDPxE4EoB?= NUnBb3BrOjRiaB?= NWezSoJNcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? NVrUeGFLOjV{Nk[wOlM>
SK-N-AS  M4HyUGZ2dmO2aX;uJGF{e2G7 MWqxNEDPxE4EoB?= Mn;wN|AhdWmw MknhbY5lfWOnczDwbI9{eGixconsZZRqd25ib3[g{tIu[2G2ZX7pckApe2W{Nke1LUwheC2JU1uz{tIhMHOnckmpJIFv\CClb37jc41qfGGwdDDobYdp\XJibHX2[Yx{KG:oIHHjeIl3\SxidX7wbI9{eGixconsZZRm\CxizsKtZ4F1\W6rbh?= MUGyOVI3PjB4Mx?=
SK-N-AS  NYfEWpNrTnWwY4Tpc44hSXO|YYm= MmfCNVAh|ryPwrC= NEjYWJMyOC9|MD:2NEBucW5? NE\nNIdqdmO{ZXHz[ZMhdGW4ZXzzJI9nKHBvzsKtZ4F1\W6rbjCod4VzPjd3KTDhcoQhcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gdE3Pui2lYYTlcolvKCi|ZYK2O|UqKGmwIDjw[ZJqMW63Y3zlZZIhemWpaX;udy=> NYXaXXVmOjV{Nk[wOlM>
SK-N-SH NHPrRXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFz1dW4yOCEQvF5CpC=> M3eyPFQ5KGh? NGTDWZRmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> MofmNlUzPjZyNkO=
HEK‐CFTR MWPGeY5kfGmxbjDBd5NigQ>? M3fxdFLjiJN3MNMg{txO M3znXlAuOTJibXnu MnXNSG1UV8Li NYjVSWVxcW6mdXPld{BiKGSxc3ZihLBl\XCnbnTlcpQhcW:maXTlJIVn\my3eNMg NGjaW2YzPTJ4M{KwOy=>
L6 NYryfm1ETnWwY4Tpc44hSXO|YYm= MVG0NEDDvU1? M1vselI1KGh? NWT2N3EzcW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v NG\6WHAzPTJ2N{W1NC=>
MIN6  MXHGeY5kfGmxbjDBd5NigQ>? M3zzUVExKM7:TdMg NFS1SIQ{KGh? NWi0WlVZcW6lcnXhd4V{KER|IH3SUmEh\XiycnXzd4lwdg>? M{TkTlI2OjRzMUK0
ventricular cardiomyocytes  M4DINmZ2dmO2aX;uJGF{e2G7 NV7DblRZOC5yMT2xNEDPxE1? MmKwbY5kemWjc3XzJEBkSU2SIHHjZ5VufWyjdHnvci=> NYnRWZJkOjV{MEOxNVM>
ventricular cardiomyocytes  NYTZXVJwTnWwY4Tpc44hSXO|YYm= MkL0NE4xOS1zMDFOwG0> M{C4NIV3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO NFT3blUzPTJyM{GxNy=>
BeWo  MlLVSpVv[3Srb36gRZN{[Xl? NXizd3JUOjBiwsXN MUG0PEBp MmDESG1UV8Li MYnpcoR2[2W|IHPlcIwh\nW|aX;u M4\xXlI2OTh2NEe3
THP-1  MmGzSpVv[3Srb36gRZN{[Xl? NEHzPWIyNzFyIN88US=> MmfWNuKhcA>? NFfZWlJFVVORwrC= Mo\Bd5VxeHKnc4Pld{BOS1BvMTDwdo9lfWO2aX;uxsA> MlX5NlUyPTR6OEK=
Huh-7 MXfGeY5kfGmxbjDBd5NigQ>? M4f3VVAuOjBizszN MoDtNkBpyqB? Mnv4doV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| MlrVNlUyODl6M{S=
C6 M3jHcmZ2dmO2aX;uJGF{e2G7 MnXJNVAh|ryPwrC= NX;CTI4zOjBibXnu NYPFXHRNcW6lcnXhd4V{KGODTWCgZYNkfW23bHH0bY9v NF[xfVgzPTB4OUSxOy=>
SW480 NIq4T2JHfW6ldHnvckBCe3OjeR?= M1XQeVQxyqEQvF2= M{\wUlQ5yqCq M3;vbGROW09? NWqyZ5hp[WO2aY\heIV{KFCSMlG= NVPWPWJjOjR7OUe0OVE>
HT-29  MVzGeY5kfGmxbjDBd5NigQ>? NXLzbGM4PDEEoN88US=> Mm\rOFjDqGh? MnixSG1UVw>? M3vXO4FkfGm4YYTld{BRWDKD M2HOXlI1QTl5NEWx
SW480 NEiwOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfsfII1OMLizszN MlvKNE04OiCq M2rTVGROW09? M2T0WYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> MUSyOFk6PzR3MR?=
HT-29  NImxNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLhOoU1OMLizszN NX7JR4FDOC15MjDo M2[1PGROW09? Ml;BbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NGrXdY4zPDl7N{S1NS=>
SW480 MV3GeY5kfGmxbjDBd5NigQ>? M4fKc|QxyqEQvF2= NEOzPW04KGR? MVzEUXNQ MnrFdoVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= NFXWb4kzPDl7N{S1NS=>
HT-29  Ml3ISpVv[3Srb36gRZN{[Xl? NEPpeVI1OMLizszN M1rh[Vch\A>? NEX2SGlFVVOR M2\yOZJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NH;iRXczPDl7N{S1NS=>
SW480 MWTBdI9xfG:|aYOgRZN{[Xl? MmS3OFDDqM7:TR?= NGLJToU1QMLiaB?= MYHEUXNQ MWfpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MXyyOFk6PzR3MR?=
HT-29  NVzOUGoySXCxcITvd4l{KEG|c3H5 M1z1PFQxyqEQvF2= M1;I[|Q5yqCq MU\EUXNQ NVXmU|lCcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 M13zcVI1QTl5NEWx
SW480 NFjnNIxCeG:ydH;zbZMhSXO|YYm= MnLmOFDDqM7:TR?= MUK0POKhcA>? M323T2ROW09? NIi5OFZqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz NXLZW2lHOjR7OUe0OVE>
HT-29  NXzLfHdvSXCxcITvd4l{KEG|c3H5 NVfWbHBTPDEEoN88US=> NV;WfWJMPDkEoHi= NFnqfYtFVVOR MWfpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| NXroVGRCOjR7OUe0OVE>

... Click to View More Cell Line Experimental Data

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.5
化学式

C22H34O7

CAS号 66575-29-9
稳定性 powder
in solvent
别名 Coleonol

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

cAMP Signaling Pathway Map

Tags: 购买Forskolin | Forskolin供应商 | 采购Forskolin | Forskolin价格 | Forskolin生产 | 订购Forskolin | Forskolin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID